Association between low body weight and cytochrome P-450 enzyme activity in patients with anorexia nervosa.

Pharmacology Research & Perspectives
Pål SandvikOlav Spigset

Abstract

Very little is known to which extent severe underweight could affect cytochrome P-450 (CYP) enzyme activity. In this study, 24 patients with anorexia nervosa at two occasions ingested single oral doses of five test drugs known to be metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, respectively. A mixed model analysis was used to evaluate the effect of changes in body mass index (BMI) on the metabolic activities of these enzymes. The primary end point was the change in drug/metabolite ratio of each of the test drugs per kg/m2 change in BMI. With increasing BMI, the metabolic activity of CYP3A4 decreased (change in the CYP3A4 drug/metabolite ratio per unit change in BMI = 0.056; 95% confidence interval [CI] 0.011 to 0.102; P = .017). For CYP1A2, increasing BMI increased the metabolic activity with borderline significance (change in the CYP1A2 drug/metabolite ratio per unit change in BMI = -0.107; CI -0.220 to 0.005; P = .059). For CYP2C9, CYP2C19, and CYP2D6, no significant changes were seen. The clinical impact of these findings for drug treatment in patients with anorexia nervosa and other severely underweight patients needs to be further studied by examining the pharmacokinetics of specific drugs. This might be part...Continue Reading

References

Mar 22, 2001·British Journal of Clinical Pharmacology·S HäggR Dahlqvist
Jun 18, 2003·Clinical Pharmacology and Therapeutics·Magnus ChristensenLeif Bertilsson
Jan 17, 2007·Journal of Clinical Psychopharmacology·Sheldon H PreskornTal Burt
Mar 1, 2012·Frontiers in Pharmacology·Hege Christensen, Monica Hermann
Mar 28, 2012·Clinical Pharmacokinetics·Margreke J E BrillCatherijne A J Knibbe
Feb 14, 2014·Drug Metabolism and Pharmacokinetics·Linda Björkhem-BergmanUlf Diczfalusy
Apr 22, 2015·Steroids·Marie Tremblay-FrancoLuigi Iuliano
Nov 29, 2015·European Journal of Clinical Pharmacology·Ole Kristian ThuBent Hellum
Apr 16, 2016·Clinical Pharmacology and Therapeutics·Yasar TasnifMary F Hebert
Oct 21, 2016·Clinical Pharmacokinetics·Gail D Anderson, Lingtak-Neander Chan
Aug 22, 2018·Endocrine, Metabolic & Immune Disorders Drug Targets·Mina RabieeMohammad Mojerloo
Sep 15, 2018·Pharmacology Research & Perspectives·Kristine HoleEspen Molden

❮ Previous
Next ❯

Citations

Mar 30, 2021·Journal of Medical Case Reports·Kanitpong Phabphal, Prut Koonalintip
Jul 25, 2021·International Journal of Molecular Sciences·Ellen Niederberger, Michael J Parnham
Dec 18, 2021·Expert Review of Clinical Pharmacology·Georgios SchoretsanitisMichael Paulzen

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

NCSS PASS

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.